Vasundhara Rasayans Ltd
Incorporated in 1987, Vasundhara Rasayans Ltd manufacturing and exporter Antacids therapeutic category of Active Pharm Ingredients
- Market Cap ₹ 64.5 Cr.
- Current Price ₹ 203
- High / Low ₹ 398 / 185
- Stock P/E 15.2
- Book Value ₹ 112
- Dividend Yield 0.99 %
- ROCE 16.4 %
- ROE 12.6 %
- Face Value ₹ 10.0
Pros
- Debtor days have improved from 61.2 to 44.6 days.
Cons
- The company has delivered a poor sales growth of 9.93% over past five years.
- Earnings include an other income of Rs.2.35 Cr.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
20.83 | 18.40 | 15.27 | 15.41 | 16.58 | 19.71 | 21.17 | 22.68 | 26.70 | 37.88 | 36.96 | 33.99 | |
17.27 | 16.80 | 13.97 | 13.76 | 14.78 | 18.55 | 18.33 | 19.57 | 24.49 | 32.32 | 30.53 | 29.95 | |
Operating Profit | 3.56 | 1.60 | 1.30 | 1.65 | 1.80 | 1.16 | 2.84 | 3.11 | 2.21 | 5.56 | 6.43 | 4.04 |
OPM % | 17.09% | 8.70% | 8.51% | 10.71% | 10.86% | 5.89% | 13.42% | 13.71% | 8.28% | 14.68% | 17.40% | 11.89% |
0.14 | 0.31 | 0.25 | 0.44 | 7.74 | 1.04 | 1.15 | 0.99 | 1.04 | 2.30 | 1.94 | 2.35 | |
Interest | 0.64 | 0.53 | 0.57 | 0.39 | 0.17 | 0.08 | 0.06 | 0.09 | 0.09 | 0.25 | 0.21 | 0.27 |
Depreciation | 0.92 | 0.50 | 0.56 | 0.56 | 0.32 | 0.05 | 0.03 | 0.05 | 0.12 | 0.13 | 0.26 | 0.36 |
Profit before tax | 2.14 | 0.88 | 0.42 | 1.14 | 9.05 | 2.07 | 3.90 | 3.96 | 3.04 | 7.48 | 7.90 | 5.76 |
Tax % | 34.11% | 34.09% | 45.24% | 59.65% | 28.07% | 29.95% | 23.59% | 25.76% | 28.62% | 25.27% | 25.82% | 26.39% |
1.41 | 0.58 | 0.24 | 0.46 | 6.52 | 1.45 | 2.99 | 2.94 | 2.17 | 5.59 | 5.86 | 4.25 | |
EPS in Rs | 4.44 | 1.82 | 0.76 | 1.45 | 20.51 | 4.56 | 9.41 | 9.25 | 6.83 | 17.59 | 18.44 | 13.37 |
Dividend Payout % | 11.28% | 27.41% | 0.00% | 69.13% | 4.88% | 21.93% | 15.95% | 16.22% | 14.65% | 11.38% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | 6% |
5 Years: | 10% |
3 Years: | 8% |
TTM: | -8% |
Compounded Profit Growth | |
---|---|
10 Years: | 22% |
5 Years: | 8% |
3 Years: | 31% |
TTM: | -27% |
Stock Price CAGR | |
---|---|
10 Years: | 24% |
5 Years: | 43% |
3 Years: | 21% |
1 Year: | -12% |
Return on Equity | |
---|---|
10 Years: | 15% |
5 Years: | 16% |
3 Years: | 18% |
Last Year: | 13% |
Balance Sheet
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 3.18 | 3.18 | 3.18 | 3.18 | 3.18 | 3.18 | 3.18 | 3.18 | 3.18 | 3.18 | 3.18 | 3.18 |
Reserves | 3.33 | 3.72 | 3.96 | 4.04 | 10.56 | 11.63 | 14.23 | 16.69 | 18.36 | 23.64 | 28.76 | 32.38 |
4.44 | 5.58 | 5.01 | 3.10 | 1.41 | 0.46 | 0.00 | 0.00 | 1.31 | 4.02 | 1.95 | 4.21 | |
3.47 | 4.16 | 3.21 | 3.13 | 5.23 | 5.56 | 7.28 | 3.14 | 2.66 | 3.68 | 3.41 | 3.30 | |
Total Liabilities | 14.42 | 16.64 | 15.36 | 13.45 | 20.38 | 20.83 | 24.69 | 23.01 | 25.51 | 34.52 | 37.30 | 43.07 |
5.79 | 7.62 | 7.28 | 6.78 | 0.10 | 0.20 | 0.30 | 0.67 | 0.91 | 0.86 | 2.43 | 2.49 | |
CWIP | 0.31 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.18 | 0.23 | 0.18 | 0.07 | 1.10 | 1.23 | 0.97 | 1.12 | 0.32 | 0.00 | 1.16 | 2.35 |
8.14 | 8.79 | 7.90 | 6.60 | 19.18 | 19.40 | 23.42 | 21.22 | 24.28 | 33.66 | 33.71 | 38.23 | |
Total Assets | 14.42 | 16.64 | 15.36 | 13.45 | 20.38 | 20.83 | 24.69 | 23.01 | 25.51 | 34.52 | 37.30 | 43.07 |
Cash Flows
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
3.18 | 1.56 | 1.32 | 2.42 | -10.70 | 0.43 | 0.36 | 0.22 | 7.90 | -6.50 | 6.03 | -5.83 | |
-0.51 | -2.02 | -0.06 | 0.07 | 13.30 | 0.53 | 1.02 | 0.16 | 1.39 | 1.27 | -1.32 | 0.46 | |
-2.88 | 0.46 | -1.28 | -2.24 | -2.26 | -1.36 | -0.87 | -0.49 | 0.79 | 2.19 | -2.88 | 1.35 | |
Net Cash Flow | -0.21 | 0.00 | -0.01 | 0.24 | 0.33 | -0.41 | 0.50 | -0.12 | 10.08 | -3.04 | 1.83 | -4.02 |
Ratios
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 65.71 | 74.39 | 93.22 | 89.53 | 131.65 | 94.63 | 107.41 | 99.30 | 100.34 | 77.57 | 61.43 | 44.56 |
Inventory Days | 39.14 | 45.71 | 53.90 | 69.11 | 64.32 | 60.51 | 59.00 | 48.01 | 57.91 | 79.48 | 38.86 | 44.33 |
Days Payable | 42.15 | 59.78 | 31.68 | 52.91 | 62.28 | 45.28 | 59.39 | 76.61 | 57.65 | 48.68 | 40.43 | 42.91 |
Cash Conversion Cycle | 62.70 | 60.32 | 115.44 | 105.73 | 133.69 | 109.85 | 107.02 | 70.70 | 100.60 | 108.36 | 59.85 | 45.98 |
Working Capital Days | 85.16 | 98.19 | 122.38 | 88.11 | 289.71 | 254.07 | 267.41 | 143.88 | 145.73 | 213.24 | 205.21 | 316.46 |
ROCE % | 24.41% | 12.04% | 8.04% | 13.44% | 14.21% | 14.14% | 23.75% | 21.73% | 12.92% | 28.79% | 25.06% | 16.37% |
Documents
Announcements
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
30 May - Annual Secretarial Compliance Report confirms full SEBI compliance for FY 2024-25, no violations or actions.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
30 May - Newspaper Advertisement pertaining to the audited financial results of the Company for the Quarter and year ended on 31.03.2025
-
Financial Results For The Quarter And Year Ended As On 31.03.2025.
28 May - Audited financial results for FY ended March 31, 2025 approved; unmodified audit opinion received.
-
Board Meeting Outcome for Board Meeting Outcome For The Outcome Of Board Meeting And Submission Of Financial Results For The Quaarter And Year Ended As On 31.03.2025
28 May - Audited financial results for FY ended March 31, 2025 approved; unmodified audit opinion received.
-
Board Meeting Intimation for Board Meeting To Be Held On 28.05.2025
21 May - Board meeting on May 28 to approve audited results for quarter/year ended March 31, 2025.
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
-
Financial Year 2009
from bse
Business Overview:[1]
Company offers wide range antacid therapeutic category of API andis also having an API intermediate plant to handle organic product